2019 ANNUAL CONVENTION 27 & 28 November Hyatt Hotel Canberra 120 Commonwealth Ave, Yarralumla ACT 2600
AAMRI MEMBERS
EVENT CONTACTS Peter Thomas 0411 600 992 [email protected] Cath Latham 0413 865 459 [email protected] Kathryn Naumenko 0402 117 529 [email protected] Aimee Sanderson 0414 611 334 [email protected]
WIFI ACCESS Select network: @Hyatt_Wifi Option: Conference Code Enter code: AAMRI2019
2
CONVENTION PROGRAM WED 27 NOV
9.00am REGISTRATION OPENS
9.30am-12.30pm MRI BUSINESS MANAGERS’ MEETING Pages 7-12 Federation Ballroom North, Hyatt Hotel Canberra Sponsored by EndpointIQ
12.30pm-1.30pm LUNCH The Gallery, Hyatt Hotel Canberra
1.30pm-5.00pm AAMRI STRATEGY MEETING Pages 13-18 Federation Ballroom, Hyatt Hotel Canberra Sponsored by EndpointIQ
5.30pm-6.30pm MRI BOARD MEMBER PRE-DINNER DRINKS The Lavender Terrace, Hyatt Hotel Canberra
6.40pm COURTESY COACHES FROM HYATT HOTEL CANBERRA TO PARLIAMENT HOUSE Depart from Kaye place, located at the rear of the Hyatt Hotel Canberra
7.00pm 2019 AAMRI ANNUAL DINNER Great Hall, Parliament House Guest speaker: The Hon Greg Hunt MP, Minister for Health Sponsored by CSL
10.15pm Courtesy coach from Parliament House to Hyatt Hotel Canberra
THU 28 NOV
7.20am-8.30am AAMRI PRESIDENT’S BREAKFAST Federation Ballroom North, Hyatt Hotel Canberra Guest speaker: The Hon Chris Bowen MP, Shadow Minister for Health
9.00am-11.00am AAMRI AGM (REGISTRATION FROM 8.30AM) Pages 19-58 Federation Ballroom North, Hyatt Hotel Canberra
3
WE WOULD LIKE TO ACKNOWLEDGE THE NGUNNAWAL PEOPLE who are the traditional custodians of the land we are meeting on today. We acknowledge and respect their continuing culture and the contribution they make to the life of this city and this region. We would like to welcome all Aboriginal and Torres Strait Islander people who may be attending today’s event.
WE THANK OUR EVENT SPONSORS
MRI Business Managers’ Meeting and AAMRI Strategy Meeting 2019 AAMRI Annual Dinner
4
FACILITATOR
PROFESSOR MOIRA CLAY Head Honcho Moira Clay Consulting
We are delighted to welcome Moira as the facilitator for the 2019 AAMRI Convention.
ABOUT MOIRA Moira Clay is regarded as one of Australia’s foremost experts in the niche area of health and medical research strategic management. She has been a vigorous advocate for researchers for close to 20 years, with extensive senior executive experience in funding bodies and medical research institutes in Victoria, New South Wales and Western Australia. She was President of two peak bodies – the Australian Society for Medical Research (2003) and the Australasian Research Management Society (2013) – leading significant public, political and scientific advocacy initiatives. She has worked closely with Federal and State Governments for >20 years. She holds an Adjunct Position as Professor with the University of Western Australia.
Moira established her research management consultancy, Moira Clay Consulting, in 2013 and has had a wide range of clients including universities, medical research institutes, professional bodies, funding bodies, and charities. Her work focuses on empowering organisations to unlock their potential, realise opportunities and overcome challenges presented by a diverse, complex and dynamic sector.
Moira combines her experiences from a successful 10 year research career in laboratory-based cardiovascular research, her achievements in research management and her extensive experience sector-wide to build bridges between organisation’s and find bold and innovative solutions to achieve research impact, sustainability and benefit.
5
6 MRI BUSINESS MANAGERS’ MEETING
WEDNESDAY 27 NOVEMBER, 9.30AM – 12.30PM Federation Ballroom North, Hyatt Hotel Canberra Facilitator: Professor Moira Clay, Moira Clay Consulting Sponsored by EndpointIQ
AGENDA 9.00am REGISTRATION OPENS
9.30am WELCOME
9.35am Discussion session 1 MANAGING UNIVERSITY-INSTITUTE RELATIONSHIPS
Introduction: Marcus Goddard
Case Study 1: Tim Regan, The George Institute for Global Health Case Study 2: Dr Carol Ginns, Peter MacCallum Cancer Centre Case Study 3: Marcus Goddard, Robinson Research Institute Followed by facilitated audience discussion
10.35am Discussion session 2 FUNDING CHALLENGES AND RESPONSES AT MRIs (PART 1) Dr Cath Latham, AAMRI MRI sector funding trends and future challenges Presentation followed by facilitated audience discussion
11.00am MORNING TEA To be held in The Gallery
11.30am Discussion session 3 FUNDING CHALLENGES AND RESPONSES FOR MRIs (PART 2) Case Study 1: Diana Forsyth, Harry Perkins Institute of Medical Research Case Study 2: Dr Chris Davis, Institute for Glycomics Case Study 3: Nick Wood, Telethon Kids Institute Followed by facilitated audience discussion
12.30pm LUNCH To be held in The Gallery
7
MRI BUSINESS MANAGERS’ MEETING
DISCUSSION SESSION 1 MANAGING UNIVERSITY-INSTITUTE RELATIONSHIPS Facilitator: Professor Moira Clay
Relationships between institutes and partner universities can be beneficial to both parties but are not without challenges. Most MRIs have agreements with university partners that cover a wide range of joint interests including grant administration, research higher degree students, infrastructure funding and services such as IT and commercialisation. While the nature of the university-institute partnerships can vary depending on the institute type (e.g. independent MRI vs university-based MRI), there are many common challenges that institutes face in managing these relationships.
In this interactive session, we will explore different university-institute partnership models through three institute case studies, followed by an open discussion from the floor.
SESSION OVERVIEW (9.35AM – 10.35AM)
9.35am Introduction: Marcus Goddard
9.40am Case Study 1: THE GEORGE INSTITUTE FOR GLOBAL HEALTH Building new university relationships Tim Regan, Chief Operating Officer
9.45am Case Study 2: PETER MACCALLUM CANCER CENTRE Managing relationships with several universities Dr Carol Ginns, Associate Director Research Support & Development
9.50am Case Study 3: ROBINSON RESEARCH INSTITUTE Challenges and opportunities for university-based medical research institutes Marcus Goddard, Business Manager
9.55am Discussion Audience discussion facilitated by Moira Clay
8 MRI BUSINESS MANAGERS’ MEETING
DISCUSSION SESSION 1 MANAGING UNIVERSITY-INSTITUTE RELATIONSHIPS
TIM REGAN Chief Operating Officer The George Institute for Global Health
Tim is the Chief Operating Officer of The George Institute for Global Health. He has extensive experience in the health, property and services industries, including as former COO of top 50 ASX- listed Mirvac Group, CEO of TJS Services, Commercial Manager for the Sydney Organising Committee for the Olympic Games and Senior Manager at PricewaterhouseCoopers. Tim is currently a Director (and former President) of Financial Executives Institute of Australia and a former Director of Thomas & Coffey and Vice-Chair of the Australian Theatre for Young People. He holds a Bachelor of Economics from the University of Sydney and is a Fellow of the Australian Institute of Company Directors, the Institute of Chartered Accountants and the Australian Property Institute.
DR CAROL GINNS Associate Director, Research Support and Development Peter MacCallum Cancer Centre
Carol came to Peter Mac in 2012 and has since held a number of senior roles, most recently as she was appointed Associate Director Research Support and Development in 2018. Carol led the detailed design of, and infrastructure procurement for, the animal facilities in the VCCC building enabling the transfer and re-establishment of Peter Mac’s extensive mouse colonies from East Melbourne. Earlier in her career, Carol completed her training in veterinary medicine and later obtained a PhD in microbiology. Since then she has filled senior management roles at The University of Melbourne, Swinburne University and in the Victorian Department of Primary Industry’s Bureau of Animal Welfare.
MARCUS GODDARD Business Manager Robinson Research Institute
As Business Manager of the Robinson Research Institute, Marcus oversees strategic and operational management, including managing key projects undertaken within the Institute. He has over 30 years’ experience in project, program and business management in private, not for profit, government and research contexts within the health research, health workforce, Aboriginal and Torres Strait Islander health, international and community development, engineering, defence and information technology sectors. He has over 9 years’ experience working within MRIs, including 5 years at Menzies School of Health Research and 4 years in his current role at the Robinson Research Institute.
9 MRI BUSINESS MANAGERS’ MEETING
DISCUSSION SESSION 2 FUNDING CHALLENGES AND RESPONSES FOR MRIS - PART 1 Discussion facilitator: Professor Moira Clay
DR CATH LATHAM Policy & Projects Manager, AAMRI
MRI SECTOR FUNDING TRENDS AND FUTURE CHALLENGES The funding landscape for medical research is in flux presenting both challenges and opportunities for the MRI sector. Recent developments such as rollout of the new NHMRC grant schemes, new research funding flowing from the MRFF and the continued funding gap for indirect costs has been driving institutes to seek more diverse sources of income to support their research programs. This has led to growth in MRI sector revenue from non-government sources, particularly commercial income and philanthropy. But what financial challenges lie on the horizon and are MRIs prepared?
In this session, we will examine past funding trends for the MRI sector, explore the size and potential impact of future challenges and how the MRI sector can be ready for what lies ahead.
ABOUT CATH Dr Cath Latham has been working in the research sector for over 18 years both in Australia and overseas. After she was awarded her PhD in 2005, Cath led a successful biomedical research career at the University of Queensland, Columbia University (NY, USA) and Burnet Institute in Melbourne before taking on a policy role at AAMRI in 2015. As AAMRI Policy and Project Manager, Cath provides evidence-based advice to members and represents MRIs on a wide range of policy issues affecting medical research and the broader research sector. Cath has been leading AAMRI’s major member-wide data collection project since 2015 where she has conducted detailed analyses of MRI sector trends in revenue, expenditure, competitive grants and workforce.
10 MRI BUSINESS MANAGERS’ MEETING
DISCUSSION SESSION 3 FUNDING CHALLENGES AND RESPONSES FOR MRIS - PART 2 Discussion facilitator: Professor Moira Clay
MRIs have been developing a number of innovative strategies to diversify their revenue streams and decrease their dependence on government funding. This shift in recent years is in response to increasing uncertainty in the medical research funding landscape which has led to nearly 60% of MRI sector revenue coming from non-government sources1. Approaches to diversifying funding vary widely among institutes and each approach brings its share of benefits and new challenges.
In this interactive session, we will explore different MRI funding models through three institute case studies followed by an open discussion from the floor.
SESSION OVERVIEW (11.30AM – 12.30PM)
11.30am Case Study 1: HARRY PERKINS INSTITUTE OF MEDICAL RESEARCH Diana Forsyth, Chief Operating Officer Optimising Institute Assets – releasing funds and increasing revenue
11.35am Case Study 2: INSTITUTE FOR GLYCOMICS Dr Chris Davis, General Manager Commercial partnerships - A growing source of funds for R&D and operations
11.40am Case Study 3: TELETHON KIDS INSTITUTE Nick Wood, Chief Operating Officer Surviving to thriving: the journey towards financial sustainability
11.45am Discussion Audience discussion facilitated by Moira Clay
1 AAMRI (2018) AAMRI Member Snapshot Report. Available at: https://aamri.org.au/aamri-member-report/
11 MRI BUSINESS MANAGERS’ MEETING
DISCUSSION SESSION 3 FUNDING CHALLENGES AND RESPONSES FOR MRIS - PART 2
DIANA FORSYTH Chief Operating Officer, Harry Perkins Institute for Medical Research
Diana’s experience spans commercial and not for profit organisations across several industries including resources, banking, and health care. Her leadership focus as an executive, management consultant and board member has been service transformation and business improvement. She worked in the UK from 2006 to 2016, where she advised Australian and European businesses and served on the boards of Cambridge University Health Partnership organisations.
DR CHRIS DAVIS General Manager, Institute for Glycomics
Having more than thirteen years management experience in innovation working at the academic/industry interface, Chris’ role is to lead a group of professionals dedicated to the strategic and operational development of the Institute for Glycomics. A core focus of the Institute is on translation of its biomedical discoveries into social and economic benefit, domestically and globally, through commercial co-development partnerships with pharma and biotech.
NICK WOOD Chief Operating Officer, Telethon Kids Institute
Nick Wood is the Chief Operating Officer and Chief Financial Officer of the Telethon Kids Institute. Telethon Kids is one of the largest and most successful child health research institutes in Australia, comprising a team of more than 700 staff and students and located at the new Perth Children’s Hospital. Telethon Kids has a vision for happy, healthy kids and is implementing a blueprint that brings together the community, researchers, health practitioners, policy makers and partners to improve the health, development and lives of children and young people through excellence in research and the application of that knowledge. Prior to working with Telethon Kids, Nick held senior leadership roles with the Western Australian Local Government Association and the Government of Western Australia.
12
AAMRI STRATEGY MEETING
WEDNESDAY 27 NOVEMBER, 1.30PM – 5.00PM Federation Ballroom, Hyatt Hotel Canberra
Chair: Professor Jonathan Carapetis AM, AAMRI President Facilitator: Professor Moira Clay, Moira Clay Consulting Sponsored by EndpointIQ
AGENDA 1.30pm WELCOME & OVERVIEW OF THE AAMRI STRATEGY MEETING Professor Jonathan Carapetis AM, AAMRI President
1.40pm EXPANDING DRUG DISCOVERY CAPABILITIES IN AUSTRALIA: THE NATIONAL DRUG DISCOVERY CENTRE Professor Guillaume Lessene and Dr Hélène Jousset Sabroux Walter and Eliza Hall Institute of Medical Research
2.00pm NHMRC’S NEW GRANT PROGRAM: THE FIRST YEAR Professor Anne Kelso AO Chief Executive Officer, National Health and Medical Research Council
2.40pm HOW HAVE THE UK FUNDING BODIES PROMOTED TRANSLATION OF HEALTH RESEARCH? Professor Sir John Savill Director of the Melbourne Academic Centre for Health
3.10pm AFTERNOON TEA To be held in The Gallery
3.40pm MAKING THE MOST OF THE MEDICAL RESEARCH FUTURE FUND Panel & audience discussion session Hosted by - Professor Moira Clay (Facilitator) Panellists: • Professor Jonathan Carapetis AM, AAMRI President and Director of Telethon Kids Institute • Professor Sir John Savill, Director of the Melbourne Academic Centre for Health • Professor Sharon Lewin AO, Director of the Doherty Institute • Professor Peter Schofield AO, Director of NeuRA • Professor Helen Christensen AO, Director of the Black Dog Institute
4.30pm AAMRI CONVENTION SHAKE-UP What would you like to see in 2020? Discussion session and audience vote
5.00pm CLOSE
13
AAMRI STRATEGY MEETING
PROFESSOR GUILLAUME LESSENE Leader, New Medicines and Advanced Technologies Theme DR HÉLÈNE JOUSSET SABROUX Head of Screening Laboratory Walter & Eliza Hall Institute of Medical Research
EXPANDING DRUG DISCOVERY CAPABILITIES IN AUSTRALIA: THE NATIONAL DRUG DISCOVERY CENTRE The Walter and Eliza Hall Institute of Medical Research has expanded its early stage drug discovery capacity to create the National Drug Discovery Centre (NDDC). Thanks to generous investments from the Australian and Victorian Governments and leveraging the Institute’s own contribution and philanthropic gifts, the NDDC will increase Australian medical researchers’ access to the latest in advanced robotic ultra-high throughput screening, addressing a critical early challenge in the drug discovery pipeline. The Centre is available to users from Australia’s academic and bio-pharmaceutical sectors.
ABOUT GUILLAUME Professor Guillaume Lessene trained as an organic chemist, completing his PhD at the University of Bordeaux, before undertaking postdoctoral work with Prof Feldman at the Pennsylvania State University. Since moving to the Institute in 2001, his major research focus has been the development of small molecules that target the apoptotic and necroptotic cell death pathways. Since January 2019, he heads the New Medicines and Advanced Technologies Theme at the Institute. This multidisciplinary Theme comprises basic research driven by structural and chemical biology, translation of basic discoveries into new medicines together with clinical research, and cutting-edge technologies. His work on targeting the BCL-2 family proteins for cancer therapy formed the basis of a major collaboration between the Institute and two pharmaceutical companies, Genentech and AbbVie, leading to the development of Venetoclax, the first BH3 mimetic approved by the Food and Drug Administration (FDA) for the treatment of chronic lymphocytic leukemia (CLL).
ABOUT HÉLÈNE Dr Hélène Jousset Sabroux is the Head of the Screening Laboratory and ACRF breakthrough technology laboratories in the New Medicines and Advanced Technologies Theme at the Walter and Eliza Hall Institute. With 12 years of experience in drug discovery gained from both industrial and academic backgrounds, she is an experienced high-throughput screener with a successful track record in leading early drug discovery projects. Her laboratory exploits state-of-the-art robotic equipment to enhance the scope and speed of the preclinical drug discovery process. Prior to joining the Institute, Dr Jousset Sabroux was a senior scientist in Merck Serono Geneva where she conceived and implemented multiple successful small molecules screening cascades that led to the discovery of valuable new assets such as the identification of lead compounds or pre-clinical candidate in the neurology and inflammation field.
14 AAMRI STRATEGY MEETING
PROFESSOR ANNE KELSO AO Chief Executive Officer National Health and Medical Research Council
NHMRC’S NEW GRANT PROGRAM: THE FIRST YEAR
ABOUT ANNE Professor Anne Kelso AO FAA FAHMS is the Chief Executive Officer of the National Health and Medical Research Council (NHMRC), the Australian Government’s lead agency for the funding of health and medical research. Following her PhD at the University of Melbourne, Professor Kelso undertook research in immunology, first at the Swiss Institute for Experimental Cancer Research in Lausanne and then at the Walter and Eliza Hall Institute of Medical Research in Melbourne and the Queensland Institute of Medical Research in Brisbane. From 2000 until 2006, she was also Director of the Cooperative Research Centre for Vaccine Technology. She then returned to Melbourne as Director of the WHO Collaborating Centre for Reference and Research on Influenza from 2007 until she took up her role with NHMRC in 2015. She is a member of several Government and international committees, including the Australian Medical Research Advisory Board (advising the Minister for Health on the strategy and priorities for the Medical Research Future Fund) and the boards of the Global Alliance for Chronic Diseases and the Human Frontier Science Program Organization.
15 AAMRI STRATEGY MEETING
PROFESSOR SIR JOHN SAVILL Executive Director Melbourne Academic Centre for Health
HOW HAVE THE UK FUNDING BODIES PROMOTED TRANSLATION OF HEALTH RESEARCH?
ABOUT SIR JOHN Sir John Savill has been Executive Director of the Melbourne Academic Centre for Health since July 2019, having served in the UK as an honorary consultant in renal and acute medicine from 1990 to 2018. John graduated in Physiological Sciences from Oxford in 1978 and in Medicine from Sheffield in 1981. He received a PhD (London) in 1989. After junior hospital appointments in Sheffield, Nottingham and London, he spent seven years in the Department of Medicine at the Royal Postgraduate Medical School, Hammersmith Hospital, with spells as an MRC Clinical Training Fellow and Wellcome Trust Senior Clinical Research Fellow.
In 1993, he moved to the Chair of Medicine at Nottingham; subsequently moving in 1998 to Edinburgh as Professor of Medicine where he set up and became the first Director of the University of Edinburgh/Medical Research Council Centre for Inflammation Research. Between 2002 and 2017 he served as the first Vice-Principal and Head of the College of Medicine and Veterinary Medicine; he was appointed to the Regius Chair of Medical Science in 2017. From 1st June 2008 to 30th September 2010, he was Chief Scientist for the Scottish Government Health Directorates (part-time). On 1st October 2010 he was appointed as Chief Executive and Deputy Chair of the Medical Research Council, combining this with Head of College duties in Edinburgh; he demitted from the MRC at the end of March 2018.
His work has been recognised by fellowships of the Royal Colleges of Physicians of London and Edinburgh, the Academy of Medical Sciences, the American Society of Nephrology, The Royal Society of Edinburgh, The Royal Society and honorary fellowships from the Royal College of Surgeons of Edinburgh and the Royal College of Paediatrics and Child Health. He was a member of the Medical Research Council from 2002 to 2008 and chaired two Research Boards during this period. He was knighted in the 2008 New Year’s Honours List for services to clinical science.
16 AAMRI STRATEGY MEETING
PANEL DISCUSSION MAKING THE MOST OF THE MEDICAL RESEARCH FUTURE FUND (MRFF) Hosted by Professor Moira Clay
PANELLISTS Professor Jonathan Carapetis AM, AAMRI President & Director of Telethon Kids Institute Professor Sir John Savill, Director of the Melbourne Academic Centre for Health Professor Sharon Lewin AO, Director of the Doherty Institute Professor Peter Schofield AO, Director of NeuRA Professor Helen Christensen AO, Director of the Black Dog Institute
The MRFF was established as a priority-driven fund for health and medical research and its translation, addressing a funding gap in Australia. Since MRFF funding started flowing in 2017 it has been difficult to determine whether it is addressing this gap, how the funding relates to the stated strategy and priorities, and how the strategy is coordinated with existing investments in medical research, such as through the NHMRC. It has even been difficult to find information about what has been funded already, how those decisions were made and what funding opportunities are on the horizon.
What do you think the MRFF should fund? How can we tackle the lack of communication and transparency around MRFF funding? What role should competitive processes play in allocating this funding and how can we best coordinate with research funded by the NHMRC?
In this interactive session, join our expert panellists in a discussion of the highs and lows of the MRFF and explore how we can achieve the best health outcomes from this significant national investment in health and medical research.
ABOUT THE MRFF The $20 billion Medical Research Future Fund (MRFF) was established as sovereign wealth fund in 2015 to fund medical research and its translation from its dividends. The MRFF is intended to fund research that addresses national health priorities leading to improved health outcomes. The fund is now at $17.5 billion and will distribute nearly $400 million for medical research during the 2019-20 financial year. At full capitalisation, it will provide $650 million every year for medical research.
More information on the MRFF is available at: https://aamri.org.au/members/mrff-info/
17 AAMRI STRATEGY MEETING
DISCUSSION AAMRI CONVENTION SHAKE-UP: WHAT WOULD YOU LIKE TO SEE IN 2020?
WHAT CHANGES WOULD YOU LIKE TO SEE FOR THE 2020 CONVENTION AND BEYOND? For this year’s convention, we have responded to member feedback and put together a program that is more discussion focussed and has more time for networking.
What other changes do you think would improve future AAMRI Conventions?
VOTE FOR YOUR PREFERRED FORMAT FOR THE 2020 AAMRI CONVENTION During this session, we’re proposing three different options for the 2020 AAMRI Convention. We’ll ask you to provide feedback and vote on which one you think you’d most like to attend in 2020.
OPTION 1 - similar to the 2019 Convention Duration One full day and one morning (until 11am) Format DAY 1 Full day MRI Business Managers Meeting – half day AAMRI Strategy meeting – half day Evening AAMRI Dinner at Parliament House
DAY 2 Morning only President’s Breakfast and AGM (until 11am)
Key features Includes an optional networking mixer on the evening before Day 1
OPTION 2 – extended second day Duration Two full days concluding at ~5pm on Day 2
Format DAY 1 Full day AAMRI Strategy meeting & AGM Evening AAMRI Dinner at Parliament House DAY 2 Full day President’s Breakfast MRI Business Managers Meeting
Key features Additional time commitment required
OPTION 3 – two full days followed by President’s Breakfast Duration Two full days and one morning (until 9am) Format DAY 1 Full day MRI Business Managers’ Meeting Evening Networking dinner – business managers
DAY 2 Full day AAMRI Strategy meeting & AGM Evening AAMRI Dinner at Parliament House
DAY 3 Breakfast only President’s Breakfast (concludes 9am)
Key features Additional time commitment required Additional networking opportunity for Business Managers (Dinner on Day 1)
18 Association of Australian Medical Research Institutes ABN 12 144 783 728
PO Box 2097 Royal Melbourne Hospital VIC 3050 [email protected] 03 9345 2500 www.aamri.org.au @AAMRI_Aus